Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« More Behind-the-Scenes Maneuvering. How Wonderful. | Main | Instrument Nostalgia »

July 26, 2013

How Rapamycin Extends Lifespan: Not By Slowing Down Aging

Email This Entry

Posted by Derek

A few years ago, there came the interesting news that rapamycin looked as if it prolonged lifespan in mice. That result is robust; it's been replicated. Now a large multicenter effort in Germany has looked closely at this effect, and they have many more details about what's going on.

The big question is: does rapamycin extend lifespan through some general effect on aging, or does it work through a non-aging mechanism (by perhaps suppressing tumor formation)? Now, many people wouldn't find that much of a distinction - would you like a drug that makes you age more slowly, or would you like one that keeps you from getting cancer? The answer would probably be "Yes". But it's a question that very much matters biochemically.

And it turns out that it's the latter. This new paper does a very careful examination of many phenotypes of aging, on both whole-animal and tissue levels, and finds that rapamycin treatment does not really seem to affect age-related changes. What changes they did see on rapamycin treatment were also present in young mice as well as older ones, making them less likely to be an underlying cause of the effect. They now believe that the compound's effect on lifespan is entirely, or almost entirely, due to the lower rate of fatal neoplasms.

Comments (8) + TrackBacks (0) | Category: Aging and Lifespan


COMMENTS

1. John Schilling on July 26, 2013 11:17 AM writes...

OK, is there some sort of prize for the most deeply-buried lead in academic publishing that these guys are going for? Rapamycin is (from an admittedly limited sample) 100% effective in preventing tumor formation in middle-aged mice, and the paper is essentially just a list of things Rapamycin doesn't prevent?

If this group ever does come up with the immortality pill, or the cure for cancer, I expect the headline will read "purported wonder drug completely fails to cure the common cold". With buried paragraph about how, because none of the test subjects ever died, they've got lots and lots of data about all the colds they caught.

Permalink to Comment

2. johnnyboy on July 26, 2013 12:05 PM writes...

@1: rapamycin is a known anti-proliferative, and it and other related limus drugs have been tested and used as anti-neoplastic agents. The fact that it had an anti-neoplastic effect in a small subset of mice is not exactly breaking news. Pushing it as such would have been an example of the over-hyping of minor findings that is often derided in this very blog.

Permalink to Comment

3. D on July 26, 2013 5:18 PM writes...

The new paper does a gat job of listing all the things rapamycin does and doesn't do. One of the major effects of rapamycin that has been described is improved cognition in old mice. How would this be achieved if rapamycin is solely an anti-neoplastic?

Permalink to Comment

4. johnnyboy on July 26, 2013 5:52 PM writes...

@3: It's not. Rapamycin inhibits the mTor pathway, which is involved in many processes, by modulating protein synthesis and breakdown. Rapamycin has multiple effects in many tissue types, in addition to its antiproliferative effects.

Permalink to Comment

5. Sili on July 27, 2013 8:59 AM writes...

I assume that a lot of impatient nuts have been taking rapamycin for years now.

Have the sideeffects shown up yet?

Permalink to Comment

6. Jim D. on July 27, 2013 12:36 PM writes...

Unfortunately it seems like it has strong potential for lung toxicity issues, albeit mainly for people with existing lung issues, along with side effects that will mimic or exacerbate type-II diabetes. Still, for the right patient, it could be useful in life extension baring these other contraindications.

Permalink to Comment

7. nitrosonium on July 29, 2013 2:12 PM writes...

speaking of mTOR inhibitors.....i have synthesized some novel mTOR inhibitors (seem to be better than sirolimus) but those who were interested have no more money. anyone out there interested??

Permalink to Comment

8. TNT on September 25, 2013 7:11 AM writes...

Hi! Any suggestions for a science project on this? One that's a bit advanced? Thanks in advance.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Biopharma Stock Events for the Rest of the Year
A Drug Candidate from NCATS
No Scripps/USC
Studies Show? Not So Fast.
Outsourced Assays, Now a Cause For Wonder?
An Alzheimer's Blood Test? Not So Fast.
AbbVie and Shire, Quietly
Catalyst Voodoo, Yielding to Spectroscopy?